EP1797096A2 - Neuartige pyrazolopyrimidine - Google Patents

Neuartige pyrazolopyrimidine

Info

Publication number
EP1797096A2
EP1797096A2 EP05786968A EP05786968A EP1797096A2 EP 1797096 A2 EP1797096 A2 EP 1797096A2 EP 05786968 A EP05786968 A EP 05786968A EP 05786968 A EP05786968 A EP 05786968A EP 1797096 A2 EP1797096 A2 EP 1797096A2
Authority
EP
European Patent Office
Prior art keywords
phenyl
biphen
group
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05786968A
Other languages
English (en)
French (fr)
Other versions
EP1797096B1 (de
Inventor
Thomas Maier
Armin Zuelch
Thomas Ciossek
Thomas Baer
Thomas Beckers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Priority to EP05786968A priority Critical patent/EP1797096B1/de
Publication of EP1797096A2 publication Critical patent/EP1797096A2/de
Application granted granted Critical
Publication of EP1797096B1 publication Critical patent/EP1797096B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to a novel class of pyrazolopyrimidine derivatives, which can be used in the pharmaceutical industry for the production of pharmaceutical compositions.
  • Pyrazolopyrimidines of certain condensation patterns are known from a variety of patent applications or patents, such as WO 2004026229, WO 2004022561 , WO 2004022560, WO 200402255, WO 2004022062, WO 2004009602, WO 2004009597, WO 2004009596, WO2004087707, WO 2003099820, WO 2003080064, EP 1348707, US 2003180924, WO 2003033499, WO 2003029209, WO 2000053605, WO 9418215 and US 6235741. It is further known that compounds of some pyrazolopyrimidine classes can act as kinase inhibitors.
  • pyrazolopyrimidine derivatives according to this invention can act as inhibitors of protein kinase B (PKB) / Akt.
  • PPKB protein kinase B
  • the invention thus relates, in a first aspect (aspect A) to compounds of formula I
  • R1 is Ar1 , or Har1 , Har2 or Har3, or
  • Ar1 is optionally substituted by R11 , and is phenyl, naphthyl, fluorenyl or Aa1 , in which Aa1 is a bisaryl radical made up of two aryl groups, which are selected independently from a group consisting of phenyl and naphthyl, and which are linked together via a single bond, R11 is 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, halogen, nitro, hydroxyl, phenoxy, phenyl-1-4C- alkoxy, hydroxy-2-4C-alkoxy, carboxy-1-4C-alkoxy or 1-4C-alkylcarbonylamino,
  • Har1 is optionally substituted by R12, and is an unsaturated monocyclic 5- or 6-membered heteroaryl radical comprising one to four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur, in which
  • R12 is 1-4C-alkyl
  • Har2 is optionally substituted by R13, and is an unsaturated fused bicyclic 9- or 10-membered heteroaryl radical comprising one to four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur, in which
  • R13 is 1-4C-alkyl
  • Har3 is optionally substituted by R14, and is an unsaturated fused tricyclic 13- or 14-membered heteroaryl radical comprising one to four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur, in which
  • R14 is 1-4C-alkyl
  • Cyc1 is a group of formula A
  • G is a 5- or 6-membered saturated or partially unsaturated heterocyclic ring comprising one or two heteroatoms independently selected from the group consisting of oxygen and sulfur, whereby said Cyc1 ring system is attached to the parent molecular group via any substitutable benzoring carbon atom,
  • Hh1 is optionally substituted by R15, and is a bisheteroaryl radical made up of two heteroaryl groups, which are selected independently from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and which are linked together via a single bond, in which R15 is 1-4C-alkyl,
  • Ah1 is optionally substituted by R16, and is an arylheteroaryl radical made up of an aryl group selected from a group consisting of phenyl and naphthyl, and a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, whereby said aryl and heteroaryl groups are linked together via a single bond, in which
  • R16 is 1-4C-alkyl
  • Ha1 is optionally substituted by R17, and is a heteroarylaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, in which
  • R17 is 1-4C-alkyl
  • each of the radicals Har1 , Har2, Har3, Hh1 and Ah1 is bonded via a ring carbon atom to the pyrazolopyrimidine scaffold;
  • R2 is hydrogen, halogen or 1-4C-alkyl
  • R3 is -T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is 1-4C-alkylene
  • R30 is -N(R301)R302, cyano, amidino, carbamoyl, guanidino, ureido, 1-4C-alkylsulfonyl, or Het2, in which
  • R301 is hydrogen, 1-4C-alkyl, 1-4C-alkoxycarbonyl, hydroxy-2-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl
  • R302 is hydrogen or 1-4C-alkyl, or R301 and R302 together an with inclusion of the nitrogen atom to which they are bonded form a radical Het1 , in which Het1 is a monocylic 3- to 7-membered saturated heterocyclic ring comprising the nitrogen atom, to which R301 and R302 are attached, and optionally one further heteroatom selected from a group consisting of oxygen, nitrogen, N(R303) and sulfur, in which R303 is hydrogen, 1-4C-alkyl or 1-4C-alkoxycarbonyl, Het2 is a monocylic 3- to 7-membered saturated heterocyclic ring, which comprises one nitrogen atom and optionally one further heteroatom selected from a group consisting of oxygen, nitrogen, N(R304) and sulfur, whereby said Het2
  • U is a bond, 1-4C-alkylene, or 1-4C-alkylene substituted with amino-1-4C-alkyl,
  • Ar2 is phenyl, or R31- and/or R32-substituted phenyl, in which
  • R31 is 1-4C-alkyl, 1-4C-alkoxy, halogen, trifluoromethyl, or -W-R311 , in which
  • W is a bond or 1-4C-alkylene
  • R311 has one of the meanings of R30 as defined afore
  • R32 is halogen
  • V is a bond
  • Har4 is optionally substituted by R33, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaryl radical comprising one to four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, whereby said Har4 radical is attached to the moiety V via a ring carbon atom, in which
  • R33 is -Z-R331 , in which
  • Z is 1-4C-alkylene
  • R331 has one of the meanings of -N(R301 )R302 as defined afore,
  • Cyc2 is a group of formula A
  • G is a 5- or 6-membered saturated heterocyclic ring comprising one nitrogen atom and optionally one further heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, whereby said Cyc2 ring system is attached to the parent molecular group via any substitutable benzoring carbon atom;
  • R4 is hydrogen or halogen; and the salts of these compounds.
  • the invention relates in a second aspect (aspect B), which is an embodiment of aspect A, to compounds of formula Ia
  • R1 is Ar1 , or
  • Ar1 is optionally substituted by R11 , and is phenyl, naphthyl, fluorenyl or Aa1 , in which Aa1 is a bisaryl radical made up of two aryl groups, which are selected independently from a group consisting of phenyl and naphthyl, and which are linked together via a single bond, R11 is 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, halogen, hydroxyl, phenoxy, phenyl-1-4C-alkoxy, hydroxy-2-4C-alkoxy, carboxy-1-4C-alkoxy or 1-4C-alkylcarbonylamino,
  • Har1 is optionally substituted by R12, and is an unsaturated monocyclic 5-or 6-membered heteroaryl radical comprising one to four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur, in which
  • R12 is 1-4C-alkyl
  • Har2 is optionally substituted by R13, and is an unsaturated fused bicyclic 9-or 10-membered heteroaryl radical comprising one to four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur, in which
  • R13 is 1-4C-alkyl
  • Har3 is optionally substituted by R14, and is an unsaturated fused tricyclic 13-or 14-membered heteroaryl radical comprising one to four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur, in which
  • R14 is 1-4C-alkyl
  • Cyc1 is a group of formula A
  • G is a 5- or 6-membered saturated or partially unsaturated heterocyclic ring comprising one or two heteroatoms independently selected from the group consisting of oxygen and sulfur, whereby said Cyc1 ring system is attached to the parent molecular group via any substitutable benzoring carbon atom,
  • Hh1 is optionally substituted by R15, and is a bisheteroaryl radical made up of two heteroaryl groups, which are selected independently from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and which are linked together via a single bond, in which
  • R15 is 1-4C-alkyl
  • Ah1 is optionally substituted by R16, and is an arylheteroaryl radical made up of an aryl group selected from a group consisting of phenyl and naphthyl, and a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, whereby said aryl and heteroaryl groups are linked together via a single bond, in which
  • R16 is 1-4C-alkyl
  • Ha1 is optionally substituted by R17, and is a heteroarylaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, in which
  • R17 is 1-4C-alkyl
  • each of the radicals Har1 , Har2, Har3, Hh1 and Ah1 is bonded via a ring carbon atom to the pyrazolopyrimidine scaffold;
  • R2 is hydrogen, halogen or 1-4C-alkyl
  • R3 is -T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is 1-4C-alkylene
  • R30 is -N(R301)R302, cyano, amidino, carbamoyl, guanidino, ureido, or Het2, in which
  • R301 is hydrogen, 1-4C-alkyl, 1-4C-alkoxycarbonyl, hydroxy-2-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl,
  • R302 is hydrogen or 1-4C-alkyl, or R301 and R302 together an with inclusion of the nitrogen atom to which they are bonded form a radical Het1 , in which Het1 is a monocylic 3- to 7-membered saturated heterocyclic ring comprising the nitrogen atom, to which R301 and R302 are attached, and optionally one further heteroatom selected from a group consisting of oxygen, nitrogen, N(R303) and sulfur, in which R303 is hydrogen, 1-4C-alkyl or 1-4C-alkoxycarbonyl,
  • Het2 is a monocylic 3- to 7-membered saturated heterocyclic ring, which comprises one nitrogen atom and optionally one further heteroatom selected from a group consisting of oxygen, nitrogen, N(R304) and sulfur, whereby said Het2 radical is attached to the parent molecular group via a ring carbon atom, in which R304 is 1-4C-alkyl,
  • U is a bond, 1-4C-alkylene, or 1-4C-alkylene substituted with amino-1-4C-alkyl,
  • Ar2 is phenyl, or R31- and/or R32-substituted phenyl, in which
  • R31 is 1-4C-alkyl, 1-4C-alkoxy, halogen, trifluoromethyl, or -W-R311 , in which
  • W is a bond or 1-4C-alkylene
  • R311 has one of the meanings of R30 as defined afore
  • R32 is halogen
  • V is a bond
  • Har4 is optionally substituted by R33, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaryl radical comprising one to four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, whereby said Har4 radical is attached to the moiety V via a ring carbon atom, in which
  • R33 is -Z-R331 , in which
  • Z is 1-4C-alkylene
  • R331 has one of the meanings of -N(R301 )R302 as defined afore,
  • Cyc2 is a group of formula A
  • G is a 5- or 6-membered saturated heterocyclic ring comprising one nitrogen atom and optionally one further heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, whereby said Cyc2 ring system is attached to the parent molecular group via any substitutable benzoring carbon atom; and the salts of these compounds.
  • 1-4C-Alkyl is a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, and, particularly, the ethyl and methyl radicals.
  • Halogen within the meaning of the present invention is iodine or, in particular, bromine, chlorine or fluorine.
  • Naphthyl alone or as part of another group, includes naphthalen-1-yl and naphthalen-2-yl.
  • 1-4C-Alkylene is a straight or branched chain alkylene radical having 1 to 4 carbon atoms.
  • straight chain alkylene radicals are the methylene (-CH 2 -), ethylene (-CH 2 -CH 2 -), trimethylene (-CH 2 -CH 2 -CH 2 -) and tetramethylene (-CH 2 -CH 2 -CH 2 -CH 2 -) radical.
  • branched chain alkylene radical is the 1 ,1-dimethyl-methylene radical.
  • 1-4C-Alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy and methoxy radicals.
  • 2-4C-Alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 2 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy radical.
  • 1-4C-Alkoxy-2-4C-alkoxy represents one of the abovementioned 2-4C-alkoxy radicals, which is substituted by one of the abovementioned 1-4C-alkoxy radicals.
  • Examples which may be mentioned are the 2-methoxyethoxy, 2-ethoxyethoxy and the 2-isopropoxyethoxy radicals.
  • Hydroxy-2-4C-alkoxy represents one of the abovementioned 2-4C-alkoxy radicals, which is substituted by a hydroxyl radical. Examples which may be mentioned are the 2-hydroxyethoxy and the 3- hydroxypropoxy radicals.
  • Carboxy-1-4C-alkoxy represents one of the abovementioned 1-4C-alkoxy radicals, which is substituted by a carboxyl radical. Examples which may be mentioned are the carboxy-methoxy, the 2-carboxy- ethoxy and the 3-carboxy-propoxy radicals.
  • Phenyl-1-4C-alkoxy represents one of the abovementioned 1-4C-alkoxy radicals, which is substituted by a phenyl radical. Examples which may be mentioned are the phenethoxy and the benzyloxy radicals.
  • 1-4C-Alkoxy-2-4C-alkyl represents one of the abovementioned 2-4C-alkyl radicals, which is substituted by one of the abovementioned 1-4C-alkoxy radicals. Examples which may be mentioned are the 2-methoxyethyl, 2-ethoxyethyl and the 2-isopropoxyethyl radicals.
  • Hydroxy-2-4C-alkyl represents one of the abovementioned 2-4C-alkyl radicals, which is substituted by a hydroxy radical. Examples which may be mentioned are the 2-hydroxyethyl and the 3-hydroxypropyl radicals.
  • Amino-1-4C-alkyl represents one of the abovementioned 1-4C-alkyl radicals, which is substituted by an amino radical. Examples which may be mentioned are the aminomethyl, 2-aminoethyl and the 3- aminopropyl radicals.
  • 1-4C-Alkylene substituted with amino-1-4C-alkyl may include, for example, one of the abovementioned 1-4C-alkylene radicals, particularly one of the abovementioned straight chain alkylene radicals, which is substituted by one of the abovementioned amino-1-4C-alkyl radicals, such as, for example, the amino-1-4C-alkyl-methylene radicals, e.g. the aminomethyl-methylene or the 2- aminoethyl-methylene radical.
  • the radical 1-4C-alkylene substituted with amino-1-4C-alkyl is bonded to the adjacent molecular groups via its 1-4C-alkylene moiety.
  • 1-4C-Alkoxycarbonyl represents a radical which, in addition to the carbonyl group, contains one of the abovementioned 1-4C-alkoxy radicals. Examples which may be mentioned are the methoxycarbonyl, the ethoxycarbonyl and the tertbutoxycarbonyl radicals.
  • An 1-4C-Alkylcarbonylamino radical is, for example, the propionylamino (C 3 H 7 C(O)NH-) and the acetylamino radical (CH 3 C(O)NH-).
  • 1-4C-Alkylsulfonyl is a sulfonyl group to which one of the abovementioned 1-4C-alkyl radicals is bonded.
  • An example is the methanesulfonyl radical (CH 3 SO 2 -).
  • Aa1 is a bisaryl radical made up of two aryl groups, which are selected independently from a group consisting of phenyl and naphthyl, and which are linked together via a single bond.
  • Aa1 may include, without being restricted thereto, a biphenyl radical, such as e.g. the 1 ,1'-biphen-3-yl or the 1 ,1'-biphen-4-yl radical.
  • a biphenyl radical such as e.g. the 1 ,1'-biphen-3-yl or the 1 ,1'-biphen-4-yl radical.
  • R11 -substituted derivatives of Aa 1 may be mentioned the following radicals:
  • substituent R11 can be attached in the ortho, or, particularly, meta or para position with respect to the binding position in which the benzene ring is bonded to the phenyl radical, such as e.g. 4'-(R11 )-1 , 1 '-biphen-3-yl or 3'-(R11 )-1 , 1 '-biphen-3-yl, or 2'-(R11 )-1 , 1 '-biphen-4-yl, 3'-(R11 )-1 , 1 '-biphen- 4-yl or 4'-(R11)-1 ,1 '-biphen-4-yl, like, for example, the 4'-fluoro-biphen-4-yl, 3'-fluoro-biphen-4-yl, T- fluoro-biphen-4-yl, 4'-methoxy-biphen-4-yl, 3'-methoxy-biphen-4-yl, 2'-meth
  • Ar1 radicals may be mentioned any one selected from the group consisting of phenyl, naphthyl such as e.g. naphthalen-1-yl or naphthalen-2-yl, fluorenyl such as e.g. fluoren-1-yl, biphenyl such as e.g. 1 ,1 '-biphen-3-yl or 1 ,1 '-biphen-4-yl;
  • 6-benzyloxy-naphthyl hydroxy-naphthyl (e.g. 6-hydroxy-naphthyl), methoxy- naphthyl (e.g. 6-methoxy-naphthyl), ethoxy-naphthyl (e.g. 6-ethoxy-naphthyl), 2-(methoxyethoxy)- naphthyl (e.g. 6-[2-(methoxyethoxy)]-naphthyl), 2-(hydroxyethoxy)-naphthyl (e.g. 6-[2-
  • Ar1 radicals may be mentioned any one selected from the group consisting of 3-benzyloxy-phenyl, 4-benzyloxy-phenyl, naphthyl, phenyl, fluoren-1-yl, biphen-4-yl, 4'-fluoro-biphen- 4-yl, 3'-fluoro-biphen-4-yl, 2'-fluoro-biphen-4-yl, 4'-methoxy-biphen-4-yl, 3'-methoxy-biphen-4-yl, T- methoxy-biphen-4-yl, 3'-acetylamino-biphen-4-yl, 6-benzyloxy-naphthalen-2-yl, 6-hydroxy-naphthalen- 2-yl, 6-methoxy-naphthalen-2-yl, 6-ethoxy-naphthalen-2-yl, 2-(methoxyethoxy)-naphthalen-2-yl, 6-[2- (methoxyethoxy)
  • Ar1 radicals may be explicitely mentioned biphen-4-yl, 4'-fluoro-biphen-4-yl, 3'- fluoro-biphen-4-yl, 2'-fluoro-biphen-4-yl, 4'-methoxy-biphen-4-yl, 3'-methoxy-biphen-4-yl, 2'-methoxy- biphen-4-yl, 3'-acetylamino-biphen-4-yl, 3'-nitro-biphen-4-yl, 4'-methoxy-biphen-3-yl, 3'-methoxy- biphen-3-yl or 3'-acetylamino-biphen-3-yl; as well as benzyloxy-naphthyl (e.g.
  • 6-benzyloxy-naphthyl hydroxy-naphthyl (e.g. 6-hydroxy-naphthyl), methoxy-naphthyl (e.g. 6-methoxy-naphthyl), ethoxy- naphthyl (e.g. 6-ethoxy-naphthyl), 2-(methoxyethoxy)-naphthyl (e.g. 6-[2-(methoxyethoxy)]-naphthyl), 2-(hydroxyethoxy)-naphthyl (e.g.
  • 6-[2-(hydroxyethoxy)]-naphthyl) such as, for example, 6-benzyloxy- naphthalen-2-yl, 6-hydroxy-naphthalen-2-yl, 6-methoxy-naphthalen-2-yl, 6-ethoxy-naphthalen-2-yl, 2- (methoxyethoxy)-naphthalen-2-yl, 6-[2-(methoxyethoxy)]-naphthalen-2-yl or 6-[2-(hydroxyethoxy)]- naphthalen-2-yl.
  • Har1 is optionally substituted by R12, and is an unsaturated monocyclic 5- or 6-membered heteroaryl radical comprising one to four heteroatoms, or, in an embodiment, one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur.
  • Har1 is optionally substituted by R12 on a ring nitrogen atom.
  • Har1 include the 5-membered ring radicals such as, without being restricted to, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, (precisely: 1 ,2,4-triazolyl or 1 ,2,3-triazolyl), thiadiazolyl (precisely: 1 ,3,4-thiadiazolyl, 1 ,2,5- thiadiazolyl, 1 ,2,3-thiadiazolyl or 1 ,2,4-thiadiazolyl) or oxadiazolyl (precisely: 1 ,3,4-oxadiazolyl, 1 ,2,5- oxadiazolyl, 1 ,2,3-oxadiazolyl or 1 ,2,4-oxadiazolyl), and the 6-membered ring radicals
  • Har2 is optionally substituted by R13, and is an unsaturated fused bicyclic 9- or 10-membered heteroaryl radical comprising one to four heteroatoms, or, in an embodiment, one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur.
  • Har2 is optionally substituted by R13 on a ring nitrogen atom.
  • Har2 include, without being restricted thereto, the benzo-fused analogues of the aforementioned monocyclic 5-membered Har1 radicals, like e.g. benzothiophenyl, benzofuranyl, indolyl, benzoxazolyl, benzothiazolyl, indazolyl, benzimidazolyl, benzisoxazolyl, benzisothiazolyl, benzoxadiazolyl (e.g.
  • benzofurazanyl benzotriazolyl, benzothiadiazolyl, isoindolyl, isobenzofuranyl or isobenzothiophenyl, or indolizinyl; and the benzo-fused analogues of the aforementioned monocyclic 6-membered Har1 radicals, like e.g. quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl or cinnolinyl, or naphthyridinyl.
  • quinolinyl isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl or cinnolinyl, or naphthyridinyl.
  • Har3 is optionally substituted by R14, and is an unsaturated fused tricyclic 13- or 14-membered heteroaryl radical comprising one to four heteroatoms, or, in an embodiment, one, two or three heteroatoms, or, in another embodiment, one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur.
  • Har3 is optionally substituted by R14 on a ring nitrogen atom.
  • Non-limiting examples of Har3 include, without being restricted to, carbazolyl, phenanthridinyl, acridinyl, carbolinyl, phenazinyl, dibenzofuranyl, dibenzothiophenyl, phenothiazinyl, phenoxazinyl, phenoxathiinyl or thianthrenyl.
  • Har3 radical may be more detailed mentioned, for example, thianthrenyl e.g. thianthren- 1-yl, dibenzothiophenyl e.g. dibenzothiophen-4-yl, or dibenzofuranyl e.g. dibenzofuran-4-yl.
  • Har3 radical may be explicitely mentioned, for example, dibenzofuranyl, such as e.g. the dibenzofuran-4-yl radical:
  • Cyc1 is a group of formula A
  • G is a 5- or 6-membered saturated or partially unsaturated heterocyclic ring comprising one or two heteroatoms independently selected from the group consisting of oxygen and sulfur, whereby said Cyc1 ring system is attached to the parent molecular group via any substitutable benzoring carbon atom.
  • Cyc1 may be mentioned, without being restricted thereto, 1 ,3-benzodioxolyl, 2,3- dihydro-1 ,4-benzodioxinyl, 2,3-dihydrobenzothiophenyl, chromanyl, chromenyl or 2,3- dihydrobenzofuranyl.
  • Cyc1 radicals may be more detailed mentioned, for example, 1 ,3-benzodioxol-5-yl.
  • Hh1 is optionally substituted by R15, and is a bisheteroaryl radical made up of two heteroaryl groups, which are selected independently from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and which are linked together via a single bond.
  • Hh1 is optionally substituted by R15 on a ring nitrogen atom.
  • Hh 1 may include, without being restricted thereto, the bithiophenyl radical, such as, for example,
  • Ah1 optionally substituted by R16, and is an arylheteroaryl radical made up of an aryl group selected from a group consisting of phenyl and naphthyl, and a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, whereby said aryl and heteroaryl groups are linked together via a single bond, and whereby Ah1 is bonded via said heteroaryl moiety to the parent molecular group.
  • Ah1 is optionally substituted by R16 on a ring nitrogen atom.
  • Ah1 may include, without being restricted thereto, the phenyl-thiophenyl or the phenyl-pyridyl radical.
  • the phenyl-pyridyl radical such as e.g. the 6-phenyl-pyridin-3-yl radical, may be mentioned.
  • Ha1 optionally substituted by R17, and is a heteroarylaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, and whereby Ha1 is bonded via said aryl moiety to the to the parent molecular group.
  • Ha1 is optionally substituted by R17 on a ring nitrogen atom.
  • a particular embodiment of said Ha1 radicals refers to heteroaryl-phenyl radicals, particularly 3-
  • Ha1 may include, without being restricted thereto, the furanyl-phenyl, the thiophenyl-phenyl, the pyrazolyl-phenyl or the pyridyl-phenyl radical.
  • R17-substituted derivatives of Ha1 [1 N-(1-4C-alkyl)-pyrazol-4-yl]-phenyl, e.g. (1-methyl-pyrazol-4-yl)-phenyl, such as the 3-(1 N-methyl-pyrazol-4-yl)-phenyl or the 4-(1 N-methyl- pyrazol-4-yl)-phenyl radical may be mentioned.
  • Har4 is optionally substituted by R33, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaryl radical comprising one to four heteroatoms, or, in an embodiment, one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulphur, whereby said Har4 radical is attached to the moiety V via a ring carbon atom.
  • Har4 is optionally substituted by R33 on a ring carbon atom.
  • Examplary Har4 radicals may include, but are not limited thereto, the monocyclic derivatives, such as e.g. furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, the bicyclic, benzo- fused analogues thereof, such as e.g.
  • quinazolinyl quinoxalinyl, cinnolinyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, indazolyl, phthalazinyl, benzothiophenyl, benzofuranyl, isobenzofuranyl, benzoxazolyl, benzothiazolyl or benzimidazolyl, as well as naphthyridinyl, indolizinyl or purinyl.
  • R33-substituted derivatives of Har4 R33-substituted pyridinyl, e.g. aminomethyl-pyridyl, or R33-substituted furanyl, e.g. aminomethyl-furanyl, radicals may be mentioned.
  • Har4 radicals may be more detailed mentioned, for example, furanyl or pyridyl.
  • Har4 radicals may be further more detailed mentioned, for example, furan-2-yl, pyridin- 4-yl, aminomethyl-pyridyl, such as e.g. 6-(aminomethyl)-pyridin-2-yl, 6-(aminomethyl)-pyridin-3-yl, 5- (aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 4-(aminomethyl)-pyridin-2-yl or 5- (aminomethyl)-pyridin-2-yl, or aminomethyl-furanyl, such as e.g. 5-(aminomethyl)-furan-2-yl.
  • aminomethyl-pyridyl such as e.g. 6-(aminomethyl)-pyridin-2-yl, 6-(aminomethyl)-pyridin-3-yl, 5- (aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 4-
  • Har4 radicals may be explicitely mentioned, for example, (aminomethyl)-pyridyl or (aminomethyl)-furanyl, such as e.g. 6-(aminomethyl)-pyridin-2-yl, 6-(aminomethyl)-pyridin-3-yl, 5- (aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 4-(aminomethyl)-pyridin-2-yl or 5- (aminomethyl)-pyridin-2-yl, or 5-(aminomethyl)-furan-2-yl.
  • (aminomethyl)-pyridyl or (aminomethyl)-furanyl such as e.g. 6-(aminomethyl)-pyridin-2-yl, 6-(aminomethyl)-pyridin-3-yl, 5- (aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 4-
  • Het1 is a monocylic 3- to 7-membered saturated heterocyclic ring comprising the nitrogen atom, to which R301 and R302 are attached, and optionally one further heteroatom selected from a group consisting of oxygen, nitrogen, N(R303) and sulphur.
  • Het1 may include, without being restricted thereto, aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl, piperidin- 1-yl, homopiperidin-1-yl, pyrazolidin-1-yl, imidazolidin-1-yl, piperazin-1-yl, homopiperazin-1-yl, morpholin-4-yl or thiomorpholin-4-yl.
  • Het1 may be mentioned, without being restricted thereto, morpholin-4-yl, 2-N- (R303)-pyrazolidin-1-yl, 3-N-(R303)-imidazolidin-1-yl, 4-N-(R303)-piperazin-1-yl or 4-N-(R303)- homopiperazin-1-yl.
  • exemplary Het1 radicals may be more detailed mentioned, for example, morpholin-4-yl or 4-N- methyl-piperazin-1 -yl.
  • Het2 is a monocylic 3- to 7-membered saturated heterocyclic ring, which comprises one nitrogen atom and optionally one further heteroatom selected from a group consisting of oxygen, nitrogen, N(R304) and sulfur, whereby said Het2 radical is attached to the parent molecular group via a ring carbon atom.
  • Het2 may include, without being restricted thereto, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, pyrazolidinyl, imidazolidinyl, piperazinyl, homopiperazinyl, morpholinyl or thiomorpholinyl.
  • Het2 may include, without being restricted thereto, 1 NH-piperidinyl including piperidin- 2-yl, piperidin-3-yl and piperidin-4-yl.
  • Het2 may be mentioned, without being restricted thereto, 1 N-(R304)- piperidinyl, such as e.g. 1 N-(R304)-piperidin-3-yl or 1 N-(R304)-piperidin-4-yl.
  • Het2 radicals may be explicitely mentioned, for example, piperidin-3-yl.
  • Cyc2 is a group of formula A
  • G is a 5- or 6-membered saturated heterocyclic ring comprising one nitrogen atom and optionally one further heteroatom selected from the group consisting of oxygen, nitrogen and sulfur, whereby said Cyc2 ring system is attached to the parent molecular group via any substitutable benzoring carbon atom.
  • Cyc2 may be mentioned, without being restricted thereto, indolinyl, isoindolinyl, 1 ,2,3,4-tetrahydroquinolinyl, 1 ,2,3,4-tetrahydroisoquinolinyl, or 3,4-dihydro-benzo[1 ,4]-oxazinyl.
  • Cyc2 radicals may be more detailed mentioned, for example, isoindolinyl or 1 ,2,3,4- tetrahydroisoquinolinyl.
  • exemplary suitable Cyc2 radicals may be explicitely mentioned, for example, 1 ,2,3,4- tetrahydroisoquinolinyl, such as e.g. 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin- 7-yl.
  • Cyc2 radicals may be more explicitely mentioned, for example, 1 ,2,3,4- tetrahydroisoquinolin-6-yl.
  • heterocyclic groups mentioned herein refer to all of the possible isomeric forms thereof.
  • heterocyclic groups mentioned herein refer, unless otherwise noted, in particular to all of the possible positional isomers thereof.
  • pyridyl or pyridinyl alone or as part of another group, includes pyridin-2- yl, pyridin-3-yl and pyridin-4-yl.
  • carbocyclic groups alone or as part of other groups, mentioned herein may be substituted by their given substituents or parent molecular groups, unless otherwise noted, at any substitutable ring carbon atom.
  • heterocyclic groups alone or as part of other groups, mentioned herein may be substituted by their given substituents or parent molecular groups, unless otherwise noted, at any possible position, such as e.g. at any substitutable ring carbon or ring nitrogen atom.
  • Rings containing imino-type ring nitrogen atoms may be preferably not substituted on these imino-type ring nitrogen atoms by the mentioned substituents or parent molecular groups. Any heteroatom of a heterocyclic ring with unsatisfied valences mentioned herein is assumed to have the hydrogen atom(s) to satisfy the valences.
  • each definition is independent.
  • Suitable salts for compounds of formula I according to this invention - depending on substitution - are all acid addition salts or all salts with bases. Particular mention may be made of the pharmacologically tolerable inorganic and organic acids and bases customarily used in pharmacy. Those suitable are, on the one hand, water-insoluble and, particularly, water-soluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic acid, methanesulphonic acid or 3-hydroxy-2- naphthoic acid, the acids being employed
  • salts with bases are - depending on substitution - also suitable.
  • salts with bases are mentioned the lithium, sodium, potassium, calcium, aluminium, magnesium, titanium, ammonium, meglumine or guanidinium salts, here, too, the bases being employed in salt preparation in an equimolar quantitative ratio or one differing therefrom.
  • Pharmacologically intolerable salts which can be obtained, for example, as process products during the preparation of the compounds of formula I according to this invention on an industrial scale, are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
  • the compounds of formula I according to this invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of formula I according to this invention as well as all solvates and in particular all hydrates of the salts of the compounds of formula I according to this invention.
  • the substituents R2 and -N(H)C(O)R3 of compounds of formula I can be attached in the ortho, meta or para position with respect to the binding position in which the phenyl ring is bonded to the pyrazolopyrimidinyl-amino moiety, whereby preference is given, in a first independent embodimenent, to the attachement of -N(H)C(O)R3 in the meta position, and particular preference is given, in a second independent embodimenent, to the attachement of -N(H)C(O)R3 in the para position.
  • the substituents R31 and R32 of compounds of formula I can be attached in the ortho, meta or para position with respect to the binding position in which the phenyl ring is bonded to the moiety U, whereby preference is given to the attachement of R31 in the meta or, particularly, in the para position.
  • the substituents R4 of compounds of formula I can be attached in the 2- or 3-position of the pyrazolo[1 ,5-c]pyrimidine scaffold, whereby preference is given to the attachement of R4 in the 3- position of the pyrazolo[1 ,5-c]pyrimidine scaffold.
  • R1 is Ar1 , or
  • Ar1 is optionally substituted by R11 , and is phenyl, naphthyl or Aa1 , in which Aa1 is biphenyl,
  • R11 is 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, halogen, hydroxyl, nitro, phenoxy, phenyl-1-4C- alkoxy, hydroxy-2-4C-alkoxy, carboxy-1-4C-alkoxy or 1-4C-alkylcarbonylamino,
  • Har3 is dibenzofuranyl
  • Ah1 is the phenyl-pyridyl radical
  • Ha1 is optionally substituted by R17 on the pyrazolyl moiety, and is the pyrazolyl-phenyl radical, in which R17 is 1-4C-alkyl;
  • R2 is hydrogen
  • R3 is T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is 1-4C-alkylene
  • R30 is -N(R301 )R302, in which
  • R301 is hydrogen, 1-4C-alkyl or hydroxy-2-4C-alkyl
  • R302 is hydrogen or 1-4C-alkyl
  • Ar2 is R31 -substituted phenyl, or R31- and R32-substituted phenyl, in which
  • R31 is amidino, guanidino, Het2 or -W-R311 , in which
  • Het2 is piperidinyl or pyrrolidinyl, whereby said Het2 radical is attached to the parent molecular group via a ring carbon atom,
  • W is a bond or 1-4C-alkylene
  • R311 has one of the foregoing meanings of R30, and
  • R32 is halogen
  • U is 1-4C-alkylene substituted with amino-1-4C-alkyl
  • Ar2 is R31- and R32-substituted phenyl, in which
  • R31 is halogen
  • R32 is halogen
  • V is a bond
  • Har4 is R33-substituted pyridyl, R33-substituted thiophenyl or R33-substituted furanyl, in which
  • R33 is -Z-R331 , in which
  • Z is 1-4C-alkylene
  • R331 has one of the foregoing meanings of R30,
  • R4 is hydrogen or bromine; and the salts of these compounds.
  • R1 is Ar1 , or
  • Ar1 is naphthalen-2-yl or 6-(R11 )-naphthalen-2-yl, in which R11 is 1-2C-alkoxy, 2-methoxyethoxy, hydroxyl, benzyloxy or 2-hydroxyethoxy, or Ar1 is biphen-3-yl, biphen-4-yl, 2'-(R11 )-biphen-3-yl, 3'-(R11 )-biphen-3-yl, 4'-(R11 )-biphen-3-yl, T-
  • Ar1 is 3-(R11 )-phenyl or 4-(R11 )-phenyl, in which
  • R11 is halogen
  • Har3 is dibenzofuran-4-yl
  • Ah1 is phenyl-pyridyl
  • Ha1 is 3-(pyrazol-1 -yl)-phenyl, 3-(1 N-H-pyrazolyl)-phenyl, 3-[1 N-(1 -2C-alkyl)-pyrazolyl]-phenyl, 4- (pyrazol-i-yl)-phenyl, 4-(1 N-H-pyrazolyl)-phenyl or 4-[1 N-(1-2C-alkyl)-pyrazolyl]-phenyl;
  • R2 is hydrogen
  • R3 is -T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is 1-4C-alkylene
  • R30 is amino, either
  • Ar2 is 2-(R31 )-phenyl, 3-(R31 )-phenyl or 4-(R31 )-phenyl, in which
  • R31 is amino, or
  • Ar2 is 3-(R31 )-phenyl or 4-(R31 )-phenyl, in which
  • R31 is guanidino, amidino or 1 N-H-piperidinyl, or
  • Ar2 is 3-(R31 )-phenyl, 4-(R31 )-phenyl, R32-substituted 3-(R31 )-phenyl, or R32-substituted 4-(R31 )- phenyl, in which
  • R31 is -W-R311 , in which
  • W is 1-4C-alkylene
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen, 1-2C-alkyl or 2-hydroxyethyl
  • R302 is hydrogen
  • R32 is fluorine, or
  • U is 1-4C-alkylene substituted with amino-1-4C-alkyl
  • Ar2 is R31- and R32-substituted phenyl, in which
  • R31 is chlorine
  • R32 is chlorine
  • V is a bond
  • Har4 is R33-substituted pyridyl, or R33-substituted furanyl, in which
  • R33 is -Z-R331 , in which
  • Z is 1-4C-alkylene, R331 is amino,
  • Cyc2 is any one of the following radicals:
  • R4 is hydrogen or bromine; and the salts of these compounds.
  • R1 is Ar1 , or
  • Ar1 is naphthalen-2-yl, or 6-(R11)-naphthalen-2-yl, in which R11 is 1-2C-alkoxy, 2-methoxyethoxy, hydroxyl, benzyloxy or 2-hydroxyethoxy, or Ar1 is biphen-3-yl, biphen-4-yl, 2'-(R11 )-biphen-4-yl, 3'-(R11 )-biphen-4-yl, 4'-(R11 )-biphen-4-yl, 3'-
  • R11 is 1-2C-alkoxy, nitro, fluorine or 1-2C-alkylcarbonylamino, or
  • Ar1 is 3-(R11 )-phenyl or 4-(R11 )-phenyl, in which R11 is bromine or iodine, Har3 is dibenzofuran-4-yl, Ah1 is 6-phenyl-pyridin-3-yl, Ha1 is 4-[1 N-(1 -2C-alkyl)-pyrazol-4-yl]-phenyl;
  • R2 is hydrogen
  • R3 is -T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is straight chain 1-4C-alkylene
  • R30 is amino, either
  • Ar2 is 4-(R31 )-phenyl or 3-(R31 )-phenyl, in which
  • R31 is guanidino, or
  • U is a bond
  • Ar2 is 4-(R31 )-phenyl, 3-(R31 )-phenyl or 2-fluoro-4-(R31 )-phenyl, in which
  • R31 is -W-R311 , in which
  • W is methylene or ethylene
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen, methyl or 2-hydroxyethyl
  • R302 is hydrogen, or
  • U is methylene substituted with amino-1-2C-alkyl
  • Ar2 is 3,4-dichloro-phenyl
  • V is a bond
  • Har4 is R33-substituted pyridyl, or R33-substituted furanyl, in which
  • R33 is -Z-R331 , in which
  • R331 is amino
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin-7-yl;
  • R4 is hydrogen or bromine; and the salts of these compounds.
  • compounds according to aspect A of this invention to be emphasized are those compounds, which are from formula Ic or, in particular, from formula Ib as shown below, and in which
  • R1 is Ar1 , or
  • Ar1 is 6-(R11 )-naphthalen-2-yl, in which
  • R11 is 1-2C-alkoxy, 2-methoxyethoxy, hydroxyl, benzyloxy or 2-hydroxyethoxy, or Ar1 is biphen-3-yl, biphen-4-yl, 2'-(R11 )-biphen-4-yl, 3'-(R11 )-biphen-4-yl, 4'-(R11 )-biphen-4-yl, 3'-
  • R11 is methoxy, fluorine, acetylamino or nitro
  • Har3 is dibenzofuran-4-yl
  • Ah1 is 6-phenyl-pyridin-3-yl
  • Ha1 is 4-(1 N-methyl-pyrazol-4-yl)-phenyl
  • R2 is hydrogen
  • R3 is -U-Ar2, -V-Har4, or Cyc2, in which either U is a bond, and
  • Ar2 is 4-(R31 )-phenyl or 3-(R31 )-phenyl, in which
  • R31 is guanidino, or
  • Ar2 is 4-(R31 )-phenyl, 3-(R31 )-phenyl or 2-fluoro-4-(R31 )-phenyl, in which
  • R31 is -W-R311 , in which
  • W is methylene or ethylene
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen or methyl
  • R302 is hydrogen
  • V is a bond
  • Har4 is 6-(aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 6-(aminomethyl)-pyridin-2-yl, 5-
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin-7-yl;
  • R4 is hydrogen; and the salts of these compounds.
  • compounds according to aspect A of this invention to be emphasized are those compounds, which are from formula Ic or, in particular, from formula Ib as shown below, and in which R1 is Ar1 , or
  • Ar1 is 6-(R11 )-naphthalen-2-yl, in which
  • R11 is 1-2C-alkoxy, 2-methoxyethoxy, hydroxyl, benzyloxy or 2-hydroxyethoxy, or Ar1 is biphen-3-yl, biphen-4-yl, 2'-(R11 )-biphen-4-yl, 3'-(R11 )-biphen-4-yl, 4'-(R11 )-biphen-4-yl, 3'-
  • R11 is methoxy, fluorine, acetylamino or nitro
  • Har3 is dibenzofuran-4-yl
  • Ah1 is 6-phenyl-pyridin-3-yl
  • Ha1 is 4-(1 N-methyl-pyrazol-4-yl)-phenyl
  • R2 is hydrogen
  • R3 is -U-Ar2, -V-Har4, or Cyc2, in which either U is a bond, and
  • Ar2 is 4-(R31 )-phenyl or 3-(R31 )-phenyl, in which
  • R31 is guanidino, or
  • Ar2 is 4-(R31 )-phenyl, 3-(R31 )-phenyl or 2-fluoro-4-(R31 )-phenyl, in which
  • R31 is -W-R311 , in which
  • W is methylene or ethylene
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen or methyl
  • R302 is hydrogen
  • V is a bond
  • Har4 is 6-(aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 6-(aminomethyl)-pyridin-2-yl, 5-
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin-7-yl;
  • R4 is bromine; and the salts of these compounds.
  • R1 is Ar1 , or
  • Ar1 is optionally substituted by R11 , and is phenyl, naphthyl or Aa1 , in which Aa 1 is biphenyl,
  • R11 is 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, halogen, hydroxyl, phenoxy, phenyl-1-4C-alkoxy, hydroxy-2-4C-alkoxy, carboxy-1-4C-alkoxy or 1-4C-alkylcarbonylamino,
  • Har3 is dibenzofuranyl
  • Cyc1 is 1 ,3-benzodioxolyl or 2,3-dihydro-1 ,4-benzodioxinyl,
  • Ah1 is the phenyl-pyridyl radical
  • Ha1 is the [1 N-(RI 7)-pyrazolyl]-phenyl radical, in which
  • R17 is 1-4C-alkyl; R2 is hydrogen;
  • R3 is -T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is 1-4C-alkylene
  • R30 is -N(R301 )R302, in which
  • R301 is hydrogen, 1-4C-alkyl or hydroxy-2-4C-alkyl
  • R302 is hydrogen or 1-4C-alkyl, or R301 and R302 together an with inclusion of the nitrogen atom to which they are bonded form a radical Het1 , in which Het1 is 4N-(R303)-piperazin-1-yl, R303 is 1-4C-alkyl,
  • Ar2 is R31 -substituted phenyl, or R31- and R32-substituted phenyl, in which
  • R31 is 1-4C-alkyl, guanidino, Het2 or -W-R311 , in which
  • Het2 is piperidinyl or pyrrolidinyl, whereby said Het2 radical is attached to the parent molecular group via a ring carbon atom,
  • W is a bond or 1-4C-alkylene
  • R311 has one of the foregoing meanings of R30, and
  • R32 is halogen
  • U is 1-4C-alkylene substituted with amino-1-4C-alkyl
  • Ar2 is R31- and R32-substituted phenyl, in which
  • R31 is halogen
  • R32 is halogen
  • V is a bond
  • Har4 is R33-substituted pyridyl, R33-substituted thiophenyl or R33-substituted furanyl, in which
  • R33 is -Z-R331 , in which
  • Z is 1-4C-alkylene
  • R331 has one of the foregoing meanings of R30,
  • R4 is hydrogen; and the salts of these compounds.
  • R1 is Ar1 , or
  • Ar1 is optionally substituted by R11 , and is naphthyl, in which
  • R11 is 1-4C-alkoxy, 1-4C-alkoxy-2-4C-alkoxy, hydroxyl, phenyl-1-4C-alkoxy or hydroxy-2-4C-alkoxy, or
  • Ar1 is optionally substituted by R11 , and is Aa1 , in which Aa1 is 1 ,1'-biphen-4-yl, and
  • R11 is 1-4C-alkoxy, fluorine or 1-4C-alkylcarbonylamino
  • Har3 is dibenzofuran-4-yl
  • Ah1 is 6-phenyl-pyridin-3-yl
  • Ha1 is 4-[1 N-(RI 7)-pyrazol-4-yl]-phenyl, in which R17 is 1-4C-alkyl;
  • R2 is hydrogen
  • R3 is -T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is 1-4C-alkylene
  • R30 is amino, either
  • Ar2 is R31 -substituted phenyl, in which
  • R31 is guanidino, 1 N-H-piperidinyl or amino, or
  • Ar2 is R31 -substituted phenyl, or R31- and R32-substituted phenyl, in which
  • R31 is -W-R311 , in which
  • W is 1-4C-alkylene
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen, 1-4C-alkyl or hydroxy-2-4C-alkyl
  • R302 is hydrogen
  • R32 is fluorine, or U is 1-4C-alkylene substituted with amino-1-4C-alkyl, and
  • Ar2 is R31- and R32-substituted phenyl, in which
  • R31 is chlorine
  • R32 is chlorine
  • V is a bond
  • Har4 is R33-substituted pyridyl, or R33-substituted furanyl, in which
  • R33 is -Z-R331 , in which
  • Z is 1-4C-alkylene
  • R331 is amino
  • Cyc2 is any one of the following radicals:
  • R4 is hydrogen; and the salts of these compounds.
  • R1 is Ar1 , or
  • Ar1 is naphthalen-2-yl, or 6-(R11)-naphthalen-2-yl, in which R11 is 1-2C-alkoxy, 2-methoxyethoxy, hydroxyl, benzyloxy or 2-hydroxyethoxy, or
  • Ar1 is biphen-4-yl, or 2'-(R11 )-biphen-4-yl, 3'-(R11 )-biphen-4-yl or 4'-(R11 )-biphen-4-yl, in which R11 is 1-2C-alkoxy, fluorine or 1-2C-alkylcarbonylamino, Har3 is dibenzofuran-4-yl, Ah1 is 6-phenyl-pyridin-3-yl, Ha1 is 4-[1 N-(RI 7)-pyrazol-4-yl]-phenyl, in which R17 is 1-2C-alkyl;
  • R2 is hydrogen
  • R3 is -T-R30, -U-Ar2, -V-Har4, or Cyc2, in which T is straight chain 1-4C-alkylene, R30 is amino, either U is a bond, and
  • Ar2 is 4-(R31 )-phenyl, or 3-(R31 )-phenyl, in which
  • R31 is guanidino, or
  • Ar2 is 4-(R31 )-phenyl, 3-(R31 )-phenyl or 2-fluoro-4-(R31 )-phenyl, in which
  • R31 is -W-R311 , in which
  • W is methylene or ethylene
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen, methyl or 2-hydroxyethyl
  • R302 is hydrogen, or
  • U is methylene substituted with amino-1-2C-alkyl
  • Ar2 is 3,4-dichloro-phenyl
  • V is a bond
  • Har4 is R33-substituted pyridyl, or R33-substituted furanyl, in which
  • R33 is -Z-R331 , in which
  • R331 is amino
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin-7-yl;
  • R4 is hydrogen; and the salts of these compounds.
  • Ar1 is 6-(R11 )-naphthalen-2-yl, in which
  • R11 is 1-2C-alkoxy, 2-methoxyethoxy, hydroxyl, benzyloxy or 2-hydroxyethoxy, or Ar1 is biphen-4-yl, 3'-acetylamino-biphen-4-yl, 2'-(R11 )-biphen-4-yl, 3'-(R11 )-biphen-4-yl, or 4'-
  • R11 (R11)-biphen-4-yl, in which R11 is methoxy, or fluorine, Har3 is dibenzofuran-4-yl, Ha1 is 4-(1 N-methyl-pyrazol-4-yl)-phenyl, R2 is hydrogen;
  • R3 is -U-Ar2, -V-Har4, or Cyc2, in which either
  • Ar2 is 4-(R31)-phenyl, in which
  • R31 is guanidino, or
  • Ar2 is 4-(R31 )-phenyl, 3-(R31 )-phenyl, or 2-fluoro-4-(R31 )-phenyl, in which
  • R31 is -W-R311 , in which
  • W is methylene or ethylene
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen or methyl
  • R302 is hydrogen
  • V is a bond
  • Har4 is 6-(aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 6-(aminomethyl)-pyridin-2-yl, 5-
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin-7-yl;
  • R4 is hydrogen; and the salts of these compounds.
  • a special interest in the compounds according to this invention refers to those compounds of formula I which are included -within the scope of this invention- by one or, when possible, by more of the following special embodiments:
  • a special embodiment (embodiment 1) of the compounds of formula I according to this invention refers to those compounds of formula I, in which
  • R1 is dibenzofuranyl, such as, in particular, dibenzofuran-4-yl.
  • R1 is naphthyl, or R11 -substituted naphthyl, such as, for example, naphthalen-1-yl or naphthalen-2-yl, or R11 -substituted naphthalen-1-yl or R11 -substituted naphthalen-2-yl, such as e.g.
  • 6-(R11)-naphthalen-1-yl or 6-(R11)- naphthalen-2-yl in particular, 6-benzyloxy-naphthalen-2-yl, 6-hydroxy-naphthalen-2-yl, 6-methoxy-naphthalen- 2-yl, 6-ethoxy-naphthalen-2-yl, 6-[2-(methoxyethoxy)]-naphthalen-2-yl or 6-[2- (hydroxyethoxy)]-naphthalen-2-yl.
  • R1 is biphenyl, or R11 -substituted biphenyl, such as, for example, biphen-3-yl, biphen-4-yl, R11 -substituted biphen-3-yl or R11 -substituted biphen-4-yl, such as e.g. 2'-(R11)-biphen-4-yl, 3'-(R11 )-biphen-4-yl or 4'-(R11)-biphen-4-yl, or
  • a sub-embodiment of embodiment 3 refers to those compounds of formula I, which are from formula
  • R1 is biphenyl, or R11 -substituted biphenyl, such as, for example, biphen-4-yl, or R11 -substituted biphen-4-yl, such as e.g. 2'-(R11)- biphen-4-yl, 3'-(R11 )-biphen-4-yl or 4'-(R11)-biphen-4-yl, in particular, 4'-fluoro-biphen-4-yl, 3'-fluoro-biphen-4-yl, 2'-fluoro-biphen-4-yl, 4'-methoxy- biphen-4-yl, 3'-methoxy-biphen-4-yl, 2'-methoxy-biphen-4-yl or 3'-acetylamino-biphen-4-yl.
  • R1 is phenyl-pyridyl, such as, in particular, 6-phenyl-pyridin-3-yl.
  • R1 is (1 N-methyl-pyrazolyl)-phenyl, such as, in particular, 4-(1 N-methyl-pyrazol-4-yl)-phenyl.
  • Another special embodiment (embodiment 6) of the compounds of formula I according to this invention refers to those compounds of formula I, in which R2 is hydrogen.
  • Another special embodiment (embodiment 7) of the compounds of formula I according to this invention refers to those compounds of formula I, in which R3 is -T-R30.
  • Another special embodiment (embodiment 8) of the compounds of formula I according to this invention refers to those compounds of formula I, in which R3 is -U-Ar2.
  • Another special embodiment (embodiment 9) of the compounds of formula I according to this invention refers to those compounds of formula I, in which R3 is -V-Har4.
  • R3 is -T-R30, in which
  • T is 1-4C-alkylene, such as e.g. trimethylene,
  • R30 is amino
  • R3 is -U-Ar2, in which
  • Ar2 is 3-(R31 )-phenyl or 4-(R31 )-phenyl, in which
  • R31 is -W-R311 , in which
  • W is a direct bond
  • R311 is amidino or guanidino, such as e.g., especially,
  • R3 is 4-guanidino-phenyl.
  • Another special embodiment (embodiment 13) of the compounds of formula I according to this invention refers to those compounds of formula I, in which R3 is -U-Ar2, in which U is a direct bond,
  • Ar2 is 3-(R31 )-phenyl or 4-(R31 )-phenyl, in which R31 is -W-R311 , in which W is a direct bond, R311 is Het2, in which
  • Het2 is bonded to W via a ring carbon atom, and is piperidinyl, pyrrolidinyl or homopiperidinyl, such as e.g. piperidin-3-yl.
  • Another special embodiment (embodiment 14) of the compounds of formula I according to this invention refers to those compounds of formula I, in which
  • R3 is -U-Ar2, in which
  • Ar2 is R31 -substituted phenyl, or R31- and R32-substituted phenyl, in which
  • R31 is -W-R311 , in which
  • W is 1-4C-alkylene, such as e.g. methylene, dimethylene or 1 ,1-dimethyl-methylene,
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen, 1-4C-alkyl or hydroxy-2-4C-alkyl, such as e.g. hydrogen, methyl or 2-hydroxy- ethyl,
  • R302 is hydrogen
  • R32 is fluorine
  • R3 is -U-Ar2, in which
  • Ar2 is 3-(R31 )-phenyl, 4-(R31 )-phenyl, or 4-(R31 )-fluoro-phenyl, in which
  • R31 is -W-R311 , in which
  • W is 1-4C-alkylene, such as e.g. methylene, dimethylene or 1 ,1-dimethyl-methylene,
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen, 1-4C-alkyl or hydroxy-2-4C-alkyl, such as e.g. hydrogen, methyl or 2-hydroxy- ethyl,
  • R302 is hydrogen
  • R3 is 4-(aminomethyl)-phenyl, 3-(aminomethyl)-phenyl,
  • R3 is 3-(R31 )-phenyl, or 4-(R31 )-phenyl, in which
  • R31 is -W-R311 , in which
  • W is 1-4C-alkylene, especially straight chain 1-4C-alkylene, such as e.g. methylene or dimethylene
  • R311 is amino, such as e.g., especially, R3 is 3-(2-aminoethyl)-phenyl, 3-(aminomethyl)-phenyl, 4-(2-aminoethyl)-phenyl or 4-
  • R3 is 3-(2-aminoethyl)-phenyl.
  • R3 is 3-(aminomethyl)-phenyl.
  • R3 is 4-(2-aminoethyl)-phenyl.
  • R3 is 4-(aminomethyl)-phenyl.
  • U is methylene substituted with amino-1-2C-alkyl
  • Ar2 is R31- and R32-substituted phenyl, in which R31 is chlorine, R32 is chlorine, such as e.g., especially,
  • R3 is 1-(2-aminoethyl)-1-(3,4-dichloro-phenyl)-methyl or 1-(aminomethyl)-1-(3,4-dichloro-phenyl)- methyl.
  • R3 is -V-Har4, in which
  • V is a direct bond
  • Har4 is R33-substituted thiophenyl, or, especially, R33-substituted pyridyl, or R33-substituted furanyl, in which R33 is -Z-R331 , in which Z is 1-4C-alkylene, such as e.g. methylene,
  • R331 is amino, such as e.g., especially, R3 is 6-(aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 6-(aminomethyl)-pyridin-2-yl, 5-
  • R3 is R33-substituted pyridyl, in which R33 is -Z-R331 , in which Z is straight chain 1-4C-alkylene, such as e.g., especially, methylene,
  • R331 is amino.
  • R3 is Cyc2, in which
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin-7-yl, especially
  • R3 is Cyc2, in which
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl.
  • R2 is hydrogen
  • Embodiment 18 refers to those compounds of formula I, in which the substituent -N(H)C(O)R3 is attached in the para position with respect to the binding position in which the phenyl ring is bonded to the pyrazolopyrimidinyl-amino moiety, the substituent R4 is attached in the 3-position of the pyrazolopyrimidine scaffold, and
  • R2 is hydrogen
  • R2 is hydrogen
  • Embodiment 19 refers to those compounds of formula I, in which the substituent -N(H)C(O)R3 is attached in the meta position with respect to the binding position in which the phenyl ring is bonded to the pyrazolopyrimidinyl-amino moiety, the substituent R4 is attached in the 3-position of the pyrazolopyrimidine scaffold, and
  • R2 is hydrogen
  • R3 is T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is straight chain 1-4C-alkylene
  • R30 is -N(R301 )R302, in which
  • R301 is hydrogen, 1-4C-alkyl or hydroxy-2-4C-alkyl
  • R302 is hydrogen
  • U is a bond, straight chain 1-4C-alkylene, or straight chain 1-4C-alkylene substituted with amino-1-
  • Ar2 is R31 -substituted phenyl, or R31- and R32-substituted phenyl, in which R31 is 1-4C-alkyl, fluorine, chlorine, guanidino, Het2, or -W-R311 , in which Het2 is bonded via a ring carbon atom to the phenyl moiety, and is pyrrolidinyl, piperidinyl or homopiperidinyl,
  • W is a bond or 1-4C-alkylene
  • R311 has any one of the foregoing meanings of R30, R32 is fluorine or chlorine,
  • V is a bond
  • Har4 is substituted by R33, and is pyridyl, furanyl or thiophenyl, in which
  • R33 is -Z-R311 , in which
  • R331 has any one of the foregoing meanings of R30,
  • R3 is T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is straight chain 1-4C-alkylene
  • R30 is -N(R301 )R302, in which
  • R301 is hydrogen, 1-2C-alkyl or hydroxy-2-3C-alkyl
  • R302 is hydrogen
  • Ar2 is R31 -substituted phenyl, or R31- and R32-substituted phenyl, in which
  • R31 is guanidino, Het2, or -W-R311 , in which
  • Het2 is bonded via a ring carbon atom to the phenyl moiety, and is pyrrolidinyl, piperidinyl or homopiperidinyl,
  • W is a bond or 1-4C-alkylene
  • R311 has any one of the foregoing meanings of R30, and
  • R32 is fluorine, or
  • U is aminomethyl-methylene, or aminoethyl-methylene
  • Ar2 is 3,4-dichlorophenyl
  • V is a bond
  • Har4 is substituted by R33, and is pyridyl, furanyl or thiophenyl,
  • R33 is -Z-R311 , in which
  • Z is 1-4C-alkylene
  • R331 has any one of the foregoing meanings of R30,
  • R3 is T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is straight chain 1-4C-alkylene
  • R30 is amino
  • Ar2 is 3-(R31 )-phenyl, 4-(R31 )-phenyl, or 3-(R31 )- or 4-(R31 )-fluorophenyl, in which
  • R31 is guanidino, Het2, amino, or -W-R311 , in which
  • Het2 is bonded via a ring carbon atom to the phenyl moiety, and is pyrrolidinyl or piperidinyl,
  • W is 1-4C-alkylene
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen, methyl or 2-hydroxy-ethyl
  • R302 is hydrogen, or
  • U is aminomethyl-methylene, or (2-aminoethyl)-methylene, and
  • Ar2 is 3,4-dichlorophenyl
  • V is a bond
  • Har4 is substituted by R33, and is thiophenyl, or, especially, pyridyl or furanyl,
  • R33 is -Z-R311 , in which
  • Z is 1-2C-alkylene
  • R331 is amino
  • R3 is T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is straight chain 1-4C-alkylene, R30 is amino,
  • Ar2 is 3-(R31 )-phenyl, 4-(R31 )-phenyl, or 2-fluoro-4-(R31 )-phenyl, in which
  • R31 is guanidino, Het2, amino, or -W-R311 , in which
  • Het2 is piperidin-3-yl
  • W is methylene, dimethylene or 1 ,1-dimethyl-methylene, especially methylene or dimethylene,
  • R311 is -N(R301 )R302, in which
  • R301 is hydrogen, methyl or 2-hydroxy-ethyl, especially hydrogen
  • R302 is hydrogen, or
  • U is aminomethyl-methylene, or (2-aminoethyl)-methylene, and
  • Ar2 is 3,4-dichlorophenyl
  • V is a bond
  • Har4 is substituted by R33, and is pyridyl or furanyl
  • R33 is -Z-R311 , in which
  • R331 is amino
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin-7-yl;
  • R3 is T-R30, -U-Ar2, -V-Har4, or Cyc2, in which
  • T is straight chain 1-4C-alkylene, such as e.g. trimethylene, R30 is amino,
  • Ar2 is 3-guanidino-phenyl, or 4-guanidino-phenyl, or
  • R31 is -W-R311 , in which W is methylene or dimethylene
  • R311 is -N(R301)R302, in which either
  • R301 is hydrogen
  • R302 is hydrogen
  • R301 is methyl or 2-hydroxy-ethyl
  • R302 is hydrogen
  • V is a bond
  • Har4 is substituted by R33, and is pyridyl or furanyl
  • R33 is -Z-R311 , in which
  • R331 is amino, such as, for example,
  • Har4 is 6-(aminomethyl)-pyridin-3-yl, 2-(aminomethyl)-pyridin-4-yl, 6-(aminomethyl)-pyridin-2-yl, 5-
  • Cyc2 is 1 ,2,3,4-tetrahydroisoquinolin-6-yl or 1 ,2,3,4-tetrahydroisoquinolin-7-yl.
  • R2 is hydrogen
  • R3 is any one selected from the group consisting of:
  • R2 is hydrogen
  • R3 is any one selected from the group consisting of:
  • R1 is any one selected from the group consisting of: dibenzofuran-4-yl, biphen-3-yl, biphen-4-yl,
  • R2 is hydrogen
  • a sub-embodiment of embodiment 22 refers to those compounds which are from formula Ib or Ic, in which
  • R1 is any one selected from the group consisting of: dibenzofuran-4-yl,
  • 6-benzyloxy-naphthalen-2-yl 6-hydroxy-naphthalen-2-yl, 6-methoxy-naphthalen-2-yl, 6-ethoxy- naphthalen-2-yl, 6-[2-(methoxyethoxy)]-naphthalen-2-yl, 6-[2-(hydroxyethoxy)]-naphthalen-2-yl, 4'-fluoro-biphen-4-yl, 3'-fluoro-biphen-4-yl, 2'-fluoro-biphen-4-yl, 4'-methoxy-biphen-4-yl, 3'- methoxy-biphen-4-yl, 2'-methoxy-biphen-4-yl, 3'-acetylamino-biphen-4-yl, 6-phenyl-pyridin-3-yl and 4-(1 N-methyl-pyrazol-4-yl)-phenyl,
  • R2 is hydrogen
  • R4 is hydrogen
  • Another special embodiment (embodiment 23) of the compounds of formula I according to this invention refers to those compounds of formula I, in which R4 is hydrogen.
  • Another special embodiment (embodiment 24) of the compounds of formula I according to this invention refers to those compounds of formula I, which are from formula Ib in which R4 is hydrogen.
  • Another special embodiment (embodiment 25) of the compounds of formula I according to this invention refers to those compounds of formula I, which are from formula Ic in which R4 is hydrogen.
  • Another special embodiment (embodiment 26) of the compounds of formula I according to this invention refers to those compounds of formula I, in which R4 is bromine.
  • Another special embodiment (embodiment 27) of the compounds of formula I according to this invention refers to those compounds of formula I, which are from formula Ib in which R4 is bromine.
  • Another special embodiment (embodiment 28) of the compounds of formula I according to this invention refers to those compounds of formula I, which are from formula Ic in which R4 is bromine.
  • Exemplary compounds according to the present invention may include, without being restricted thereto, any compounds of formula I selected from the group consisting of those compounds of formula I disclosed in the following examples as final compounds, particularly any compounds of formula I selected from those compounds of formula I listed in any of the Tables A to H in the appended "Biological Investigations", as well as the salts thereof.
  • the compounds according to the invention can be prepared, for example, as described as follows and according to the following specified reaction steps, or, particularly, in a manner as described by way of example in the following examples, or analogously or similarly thereto according to preparation procedures or synthesis strategies known to the person skilled in the art.
  • compounds of the formula V in which R1 has one of the meanings mentioned above, can be converted into corresponding compounds of formula IV with the aid of e.g. thiosemicarbazide.
  • Said cyclization reaction can be carried out as known to the skilled person or as described in the following examples, advantageously in a suitable solvent, for example an alcohol (e.g. ethanol) at elevated temperature, such as e.g. reflux temperature of ethanol.
  • a suitable solvent for example an alcohol (e.g. ethanol) at elevated temperature, such as e.g. reflux temperature of ethanol.
  • the intermediate obtained can than be cyclized to compounds of formula V, or, alternatively, it can be directly converted with thiosemicarbazide via abovementioned cyclization reaction into compounds of formula IV.
  • Said reactions can be carried out in a manner customary per se to the skilled person or as described in the following examples.
  • ketone enolate mentioned can be obtained in situ, as it is known per se to the skilled person, with the aid of a suitable base, like lithium hexamethyldisilazide at reduced temperature as described in the following examples.
  • Compounds of formula IV can be converted into compounds of formula III by alkylation, particularly methylation, reaction, and then, optionally, introduction of the radical R4, in which R4 is halogen, particularly bromine.
  • R4 is halogen, particularly bromine.
  • Compounds of formula III can be oxidized to obtain corresponding compounds of formula II, in which R4 stands for hydrogen or halogen.
  • Said steps can be performed as it is known to the skilled person or as described in the following examples, using e.g. methyl iodide as methylation reagent, a suitable halogenating reagent, such as e.g., when R4 is bromine, N-bromosuccinimide giving predominantly the 3-bromo-pyrazolo[1 ,5- c]pyrimidine derivatives, and a suitable peracid (e.g. m-chloroperbenzoic acid) as oxidation reagent.
  • a suitable halogenating reagent such as e.g., when R4 is bromine, N-bromosuccinimide giving predominantly the 3-bromo-pyrazolo[1 ,5- c]pyrimidine derivatives
  • a suitable peracid e.g. m-chloroperbenzoic acid
  • compounds of formula I in which R1 , R2, R3 and R4 have the meanings mentioned above, can be also obtained from compounds of formula Vl by reaction with compounds of formula R3-C(O)-Y, in which Y is hydroxyl and R3 stands for the substituents given above, which can be, if necessary, protected by temporary protective groups known to the person skilled in the art (such as e.g. the tertbutoxycarbonyl protective group for an amino function), by reaction with amide bond linking reagents known to the person skilled in the art and subsequential optional removal of said temporary protective groups.
  • amide bond linking reagents known to the person skilled in the art which may be mentioned are, for example, the carbodiimides (e.g.
  • azodicarboxylic acid derivatives e.g. diethyl azodicarboxylate
  • uronium salts e.g. O-(benzotriazol-1-yl)-N,N,N',N'-te
  • preferred amide bond linking reagents are uronium salts and, particularly, carbodiimides, preferably, 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride.
  • compounds of formula I in which R1 , R2, R3 and R4 have the meanings mentioned above, can be also obtained from compounds of formula Il by reaction with compounds of formula VIII, in which R2 has the meanings indicated above and R3 stands for the substituents given above which can be, if necessary, protected by temporary protective groups known to the person skilled in the art (such as e.g. the tertbutoxycarbonyl protective group for an amino function), and subsequential optional removal of said temporary protective groups.
  • temporary protective groups known to the person skilled in the art (such as e.g. the tertbutoxycarbonyl protective group for an amino function), and subsequential optional removal of said temporary protective groups.
  • compounds accessible as described herein which contain a (hetero)aromatic ring substituted by iodine or bromine or trifluoromethansulfonyloxy such as e.g., without being restricted thereto, compounds of formula I or III, in which R1 is a (hetero)aromatic ring, particularly phenyl, substituted by iodine or bromine and R4 is hydrogen, or compounds of formula I or III, in which R1 is a (hetero)aromatic ring, particularly phenyl, substituted by iodine and R4 is bromine, can be subjected to a CC-bond formation reaction (e.g.
  • aryl-aryl coupling with suitable (hetero)aryl derivatives to give corresponding compounds containing a (hetero)aryl-(hetero)aryl radical.
  • Said CC-bond formation reaction may be also, for example, a Kumada coupling, a Negishi coupling, a Hiyama coupling, a Stille reaction or, particularly, a Suzuki coupling reaction.
  • compounds of formula I or III in which R1 is a (hetero)aromatic ring substituted by iodine or bromine, can be reacted with (hetero)aryl-boronic acids or esters, such as, for example, phenyl-boronic acids (such as e.g. R11 -substituted phenyl-boronic acids), to obtain a corresponding CC-coupled group, such as, for example, a (hetero)aryl-(hetero)aryl, e.g. a bisaryl or, in more detail, bisphenyl group.
  • (hetero)aryl-boronic acids or esters such as, for example, phenyl-boronic acids (such as e.g. R11 -substituted phenyl-boronic acids)
  • a CC-coupled group such as, for example, a (hetero)aryl-(hetero)aryl, e.g. a bisary
  • the Suzuki reaction can be carried out as it is known to the person of ordinary skill in the art and/or in a manner as it is described below and specified by way of example in the following examples or analogously or similarly thereto.
  • the Suzuki reaction mentioned can be carried out in organic solvents alone, for example in toluene, benzene, dimethylformamide or in ethereal (e.g. dimethoxyethane or dioxane) or alcohol solvents or in a mixture thereof, or preferably in a mixture comprising an organic solvent (e.g. dimethoxyethane) and water, with organic (e.g. triethylamine) or preferably inorganic base (e.g.
  • potassium hydroxide thallium hydroxide, sodium bicarbonate, cesium carbonate, cesium fluoride or, in particular, potassium or sodium carbonate
  • a transition metal catalyst for example, a nickel or, in particular, palladium catalyst (e.g. Pd(OAc) 2 , PdCI 2 (PPh 3 J 2 or Pd(PPh 3 J 4 ), and, optionally, lithium chloride.
  • compounds of a given formula which can be prepared as described herein, may converted into further compounds of the respective formula by methods known to one of ordinary skill in the art.
  • compounds of formula I can be converted into further compounds of formula I by methods known to one of ordinary skill in the art. More specifically, for example, from compounds of the formula I in which a) R11 is benzyloxy, the corresponding free hydroxy compounds can be obtained by hydrogenation reactions; b) R11 is hydroxyl, the corresponding O-ether compounds can be obtained by etherification reactions; c) R301 or R303 is 1-4C-alkoxycarbonyl, such as e.g.
  • R30 is a cyano group, the corresponding amidino group can be obtained by imidoester formation and subsequential amination.
  • R301 and/or R302 is hydrogen, the corresponding N-ether compounds can be obtained by etherification reactions.
  • R30 is an amino group, the corresponding guanidino group can be obtained by guanidination reaction with the aid of suitable guanidino forming agents.
  • compounds of the formula I can be converted into their salts, or, optionally, salts of the compounds of the formula I can be converted into the free compounds.
  • Corresponding processes are habitual per se to the skilled person.
  • the substances according to the invention are isolated and purified in a manner known per se, for example by distilling off the solvent under reduced pressure and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example, column chromatography on a suitable support material.
  • Salts can be obtained by dissolving the free compound in a suitable solvent (e.g. a ketone, such as acetone, methyl ethyl ketone or methyl isobutyl ketone, an ether, such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low-molecular-weight aliphatic alcohol, such as ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added.
  • the salts can be obtained by filtering, reprecipitating, precipitating with a nonsolvent for the addition salt or by evaporating the solvent. Salts obtained can be converted into the free compounds, which can in turn be converted into salts, by alkalization or by acidification. In this manner, pharmacologically unacceptable salts can be converted into pharmacologically acceptable salts.
  • mp stands for melting point, h for hour(s), min for minutes, cone, for concentrated, Boc for the tertbutoxycarbonyl group, calc. for calculated, fnd. for found, and other abbreviations have their meanings customary per se to the skilled person.
  • the mixture is diluted with ethyl acetate and filtered over silica gel.
  • the product is partitioned between ethyl acetate and an aqueous solution of sodium bicarbonate (5%), the organic phase is dried over sodium sulfate and the crude product is purified by silica gel flash chromatography. A nearly colorless solid (0.3 g) in 50 % yield is obtained.
  • aou loios ⁇ sTssC ⁇ rD ⁇ Zsu ⁇ ⁇ y) io m ⁇ io ⁇ oos (ouu ms) is ⁇ i ⁇ o xo s ⁇ iyx i ⁇ oip ⁇ rasur ⁇ .
  • the compounds according to the present invention have valuable pharmacological properties, which can make them commercially applicable.
  • pyrazolopyrimidine derivatives according to this invention can act as inhibitors of the protein kinase B (PKB) / Akt and exhibit cellular activity; and these pyrazolopyrimidine compounds are expected to be commercially applicable in the therapy of diseases responsive to the inhibition of this protein kinase.
  • PPKB protein kinase B
  • the protein kinase B (PKB) / Akt is a serine/threonine specific protein kinase, which, for example, plays an important role for regulating cell survival and apotosis in human cancer.
  • the protein kinase B (PKB) / Akt with the isoforms Akt1 (PKB ⁇ ), Akt2 (PKB ⁇ ) and Akt3 (PKB ⁇ ) is of particular importance.
  • PKT protein kinase A
  • compounds according to this invention may be inhibitors of mentioned protein kinase activity in cells and tissues which might cause a shift towards dephosphorylated substrate proteins and as potential functional consequence, for example the induction of apoptosis, cell cycle arrest or sensitization towards chemotherapeutic or target-specific anti-cancer drugs.
  • compounds according to this invention may exhibit anti-proliferative properties. Accordingly, these compounds can be useful for anti-proliferation treatment of malignant cells. Therefore, compounds according to this invention are expected for use in the induction of a proliferation arrest in mammals such as humans.
  • compounds according to this invention can be useful in treating, preventing, inhibiting or ameliorating diseases of benign or malignant behaviour as described herein, such as e.g. (hyper)proliferative diseases.
  • compounds according to this invention can be be useful in treating, preventing, inhibiting or ameliorating of benign or malignant neoplasia, such as cancer.
  • a “neoplasia” is defined by cells displaying aberrant cell proliferation and/or survival and/or a block in differentiation.
  • a “benign neoplasia” is described by hyperproliferation of cells, incapable of forming an aggressive, metastasizing tumor in-vivo.
  • a "malignant neoplasia” is described by cells with multiple cellular and biochemical abnormalities, capable of forming a systemic disease, for example forming tumor metastasis in distant organs.
  • malignant neoplasia also described as cancer.
  • malignant neoplasia include solid and haematological tumors.
  • Solid tumors can be exemplified by tumors of the breast, bladder, bone, brain, central and peripheral nervus system, colon, endocrine glands (e.g. thyroid and adrenal cortex), esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva.
  • endocrine glands e.g. thyroid and adrenal cortex
  • Malignant neoplasia include inherited cancers exemplified by Retinoblastoma and Wilms tumor.
  • malignant neoplasia include primary tumors in said organs and corresponding secondary tumors in distant organs ("tumor metastases").
  • Hematological tumors can bee exemplified by aggressive and indolent forms of leukemia and lymphoma, namely non-Hodgkins disease, chronic and acute myeloid leukemia (CML / AML), acute lymphoblastic leukemia (ALL), Hodgkins disease, multiple myeloma and T-cell lymphoma.
  • myelodysplastic syndrome plasma cell neoplasia
  • paraneoplastic syndromes cancers of unknown primary site as well as AIDS related malignancies.
  • a cancer disease as well as a malignant neoplasia does not necessarily require the formation of metastases in distant organs. Certain tumors exert devastating effects on the primary organ itself through their aggressive growth properties. These can lead to the destruction of the tissue and organ structure finally resulting in failure of the assigned organ function.
  • Compounds according to the present invention may commercially applicable for treatment, prevention or amelioration of the diseases of benign and malignant behavior as described herein, such as e.g. cancer, like those cancer diseases described above.
  • Neoplastic cell proliferation might also effect normal cell behaviour and organ function. For example the formation of new blood vessels, a process described as neovascularization, is induced by tumors or tumor metastases.
  • Compounds according to this invention can be commercially applicable for treatment of pathophysiological relevant processes caused by benign or neoplastic cell proliferation, such as but not limited to neovascularization by unphysiological proliferation of vascular endothelial cells.
  • Drug resistance is of particular importance for the frequent failure of standard cancer therapeutics. This drug resistance is caused by various cellular and molecular mechanisms.
  • One aspect of drug resistance is caused by constitutive activation of anti-apoptotic survival signals with PKB/Akt as a key signalling kinase.
  • Inhibition of PKB/Akt might lead to a resensitization towards standard chemotherapeutic or target specific cancer therapeutics.
  • the commercial applicability of compounds according to this invention may not be limited to 1 st line treatment of cancer patients.
  • cancer patients with resistance to cancer chemotherapeutics or target specific anti-cancer drugs may be also amenable for treatment with these compounds for e.g. 2 nd or 3 rd line treatment cycles.
  • compounds according to this invention might be used in combination with standard chemotherapeutic or targeted drugs to resensitize tumors towards these agents.
  • Compounds according to this invention might also be useful in inhibiting tumor angiogenesis and metastasis.
  • Chemoprevention means in this connection the inhibition of the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of premalignant cells that have already suffered an insult or inhibiting tumor relapse.
  • compounds according to this invention may be yet further useful in the treatment of cancers associated with irregularities in the activity of Akt.
  • cancers include, but are not limited to ovarian, pancreatic and breast cancer.
  • compounds according to this invention may be also useful in the treatment of any disease process which features abnormal cellular proliferation, for example benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, dermatoses, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, or fungal infections.
  • any disease process which features abnormal cellular proliferation, for example benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, dermatoses, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, or fungal infections.
  • compounds according to this invention may be cellular active, i.e. they may exhibit any cellular effect, in particular dephosphorylation of defined substrate proteins causing, as an example, induction of apoptosis or chemosensitization.
  • chemosensitization is understood in a broad sense as sensitizing neoplastic cells for apoptotic stimuli in general. These stimuli include, for example, effectors of death receptor and survival pathways as well as cytotoxic / chemotherapeutic and targeted agents and finally also radiation.
  • apoptosis and analogous terms are used to identify a compound which excecutes programmed cell death in cells contacted with that compound alone or in combination with other compounds routinely used for therapy.
  • Apoptosis is defined by complex biochemical events within the contacted cell, such as the activation of cystein specific proteinases ("caspases") and the fragmentation of chromatin. Induction of apoptosis in cells contacted with the compound might not necessarily coupled with inhibition of cell proliferation.
  • the inhibition of proliferation and/or induction of apoptosis are specific to cells with aberrant cell growth.
  • Some of the compounds according to this invention may induce cellular effects as mentioned herein alone or in combination with standard cytotoxic or targeted cancer drugs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05786968A 2004-09-06 2005-09-05 Pyrazolopyrimidine als hemmer der proteinkinase b (akt) Expired - Lifetime EP1797096B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05786968A EP1797096B1 (de) 2004-09-06 2005-09-05 Pyrazolopyrimidine als hemmer der proteinkinase b (akt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04104283 2004-09-06
PCT/EP2005/054366 WO2006027346A2 (en) 2004-09-06 2005-09-05 Novel pyrazolopyrimidines
EP05786968A EP1797096B1 (de) 2004-09-06 2005-09-05 Pyrazolopyrimidine als hemmer der proteinkinase b (akt)

Publications (2)

Publication Number Publication Date
EP1797096A2 true EP1797096A2 (de) 2007-06-20
EP1797096B1 EP1797096B1 (de) 2011-07-27

Family

ID=34929540

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05786968A Expired - Lifetime EP1797096B1 (de) 2004-09-06 2005-09-05 Pyrazolopyrimidine als hemmer der proteinkinase b (akt)

Country Status (8)

Country Link
US (1) US7745446B2 (de)
EP (1) EP1797096B1 (de)
JP (1) JP5334414B2 (de)
AT (1) ATE517901T1 (de)
AU (1) AU2005281704A1 (de)
CA (1) CA2578384A1 (de)
ES (1) ES2368930T3 (de)
WO (1) WO2006027346A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JP2009528354A (ja) 2006-02-28 2009-08-06 メルク エンド カムパニー インコーポレーテッド ヒストン脱アセチル化酵素のインヒビター
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
AU2007307489A1 (en) * 2006-10-06 2008-04-17 Takeda Pharmaceutical Company Limited Combination drug
WO2008083288A2 (en) 2006-12-29 2008-07-10 Gloucester Pharmaceuticals Purifiction of romidepsin
EP3103791B1 (de) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino-derivate als histondeacetylase-hemmer
WO2009005638A2 (en) 2007-06-27 2009-01-08 Merck & Co., Inc. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
JP2013516420A (ja) 2009-12-30 2013-05-13 アークル インコーポレイテッド 置換されたピロロ−アミノピリミジン化合物
EP2526102B1 (de) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III PI3-kinase-inhibitoren
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
SG10201505475XA (en) 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
NZ628394A (en) * 2012-04-24 2016-02-26 Glaxosmithkline Ip No 2 Ltd Treatment method for steroid responsive dermatoses
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
EP0684953A4 (de) 1993-02-03 1999-12-22 Gensia Inc Adenosinkinase-inhibitoren die hyxofuranosyl-derivate enthalten.
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2002083675A2 (en) * 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
ES2309206T3 (es) 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
PL369742A1 (en) 2001-10-15 2005-05-02 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
WO2003082341A1 (en) * 2002-03-22 2003-10-09 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
ATE478872T1 (de) 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US7181868B2 (en) 2002-06-26 2007-02-27 Nike, Incorporated Article of footwear having a sole with a flex control member
JP2006514918A (ja) 2002-07-23 2006-05-18 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
WO2004009597A2 (en) 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as protein kinase inhibitors
JP2005536517A (ja) 2002-07-23 2005-12-02 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
WO2004022561A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
KR20050057139A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
MY137843A (en) * 2002-09-04 2009-03-31 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539163A (en) 2002-09-04 2007-03-30 Schering Corp Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors
AU2003258662A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006027346A2 *

Also Published As

Publication number Publication date
ES2368930T3 (es) 2011-11-23
US20070254046A1 (en) 2007-11-01
EP1797096B1 (de) 2011-07-27
JP2008512359A (ja) 2008-04-24
JP5334414B2 (ja) 2013-11-06
CA2578384A1 (en) 2006-03-16
WO2006027346A3 (en) 2006-08-03
ATE517901T1 (de) 2011-08-15
WO2006027346A2 (en) 2006-03-16
US7745446B2 (en) 2010-06-29
AU2005281704A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
EP1797096B1 (de) Pyrazolopyrimidine als hemmer der proteinkinase b (akt)
AU2008300827B2 (en) Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
US8575193B2 (en) N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
EP1763526B1 (de) 4,6-disubstitutierte pyrimidine und deren verwendung als proteinkinase-hemmer
EP2396331B1 (de) Kondensierte pyrimidine als akt-inhibitoren
US20090163538A1 (en) Tetrahydropyridothiophenes For Use In The Treatment Of Cancer
MX2010010014A (es) Sales de (e)-n-(2-amino-fenil)-3-{1-[4-(1-metil-1h-pirazol-4-il)-b encensulfonil]-1h-pirrol-3-il}-acrilamida.
JP5469604B2 (ja) 新規テトラヒドロ融合ピリジン
US7714134B2 (en) Compounds and use of tetrahydropyridothiophenes
AU2006205797A1 (en) Pyrrolodihydroisoquinolines as antiproliferative agents
US20090209534A1 (en) Novel compounds and use of tetrahydropyridopyridothiophenes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070410

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NYCOMED GMBH

17Q First examination report despatched

Effective date: 20080826

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT)

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005029240

Country of ref document: DE

Effective date: 20110915

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110727

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2368930

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20111123

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 517901

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111128

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111028

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602005029240

Country of ref document: DE

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE

Effective date: 20120110

Ref country code: DE

Ref legal event code: R081

Ref document number: 602005029240

Country of ref document: DE

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER: ALTANA PHARMA AG, 78467 KONSTANZ, DE

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

26N No opposition filed

Effective date: 20120502

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110905

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005029240

Country of ref document: DE

Effective date: 20120502

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602005029240

Country of ref document: DE

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER: BAYER PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE

Effective date: 20130410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20111027

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Effective date: 20130909

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110727

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20130828

Year of fee payment: 9

Ref country code: DE

Payment date: 20130829

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20130910

Year of fee payment: 9

Ref country code: GB

Payment date: 20130904

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20130913

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005029240

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140905

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140905

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140905

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20151027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140906

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20160901 AND 20160907